576 related articles for article (PubMed ID: 15199612)
1. Development of the proteasome inhibitor Velcade (Bortezomib).
Adams J; Kauffman M
Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
[TBL] [Abstract][Full Text] [Related]
2. Potential for proteasome inhibition in the treatment of cancer.
Adams J
Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
[TBL] [Abstract][Full Text] [Related]
3. Clinical update: proteasome inhibitors in solid tumors.
Lenz HJ
Cancer Treat Rev; 2003 May; 29 Suppl 1():41-8. PubMed ID: 12738242
[TBL] [Abstract][Full Text] [Related]
4. Clinical update: proteasome inhibitors in hematologic malignancies.
Richardson P
Cancer Treat Rev; 2003 May; 29 Suppl 1():33-9. PubMed ID: 12738241
[TBL] [Abstract][Full Text] [Related]
5. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
6. The proteasome: structure, function, and role in the cell.
Adams J
Cancer Treat Rev; 2003 May; 29 Suppl 1():3-9. PubMed ID: 12738238
[TBL] [Abstract][Full Text] [Related]
7. Targeting the ubiquitin-proteasome pathway in breast cancer.
Cardoso F; Ross JS; Picart MJ; Sotiriou C; Durbecq V
Clin Breast Cancer; 2004 Jun; 5(2):148-57. PubMed ID: 15245620
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitors in the treatment of B-cell malignancies.
Schenkein D
Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Schwartz R; Davidson T
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
[TBL] [Abstract][Full Text] [Related]
10. The role of proteasome inhibitors in solid tumors.
Park DJ; Lenz HJ
Ann Med; 2004; 36(4):296-303. PubMed ID: 15224656
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition: a novel approach to cancer therapy.
Adams J
Trends Mol Med; 2002; 8(4 Suppl):S49-54. PubMed ID: 11927288
[TBL] [Abstract][Full Text] [Related]
12. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib as a potential treatment for prostate cancer.
Papandreou CN; Logothetis CJ
Cancer Res; 2004 Aug; 64(15):5036-43. PubMed ID: 15289299
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition in cancer: development of PS-341.
Adams J
Semin Oncol; 2001 Dec; 28(6):613-9. PubMed ID: 11740819
[TBL] [Abstract][Full Text] [Related]
16. Development of the proteasome inhibitor PS-341.
Adams J
Oncologist; 2002; 7(1):9-16. PubMed ID: 11854543
[TBL] [Abstract][Full Text] [Related]
17. Proteasome: an emerging target for cancer therapy.
Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
[TBL] [Abstract][Full Text] [Related]
18. "Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D.
Bold R
Cancer Invest; 2004; 22(2):328-9. PubMed ID: 15199617
[No Abstract] [Full Text] [Related]
19. [Proteasome inhibitors].
Hatake K; Mishima Y; Terui Y
Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
[TBL] [Abstract][Full Text] [Related]
20. [Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells].
Satou Y; Matsuoka M
Nihon Rinsho; 2004 Jul; 62(7):1363-7. PubMed ID: 15283157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]